Product Description
| Download Documents | |
| Product Sheet | |
| SDS | COA_Lot S479.S15.1018C |
Deruxtecan is an exatecan (Exa) derivative appended with a cleavable peptide linker. It is a very potent inhibitor of topoisomerase I and an anticancer agent. Deruxtecan is used to prepare antibody-drug conjugates (ADCs), such as trastuzumab Deruxtecan (T-DXd, also known as Enhertu®, Daiichi Sankyo), targeting HER2. Deruxtecan is approved in HER2-expressing breast (BC) and gastric (GC) cancers. This BSA-Deruxtecan conjugate is designed with the same linker chemistry as PDCs prepared using our Protein Deruxtecan Conjugation Kit (Cat#: CM11432). The BSA-Deruxtecan conjugate is synthesized at CellMosaic and has an average loading of 3 to 5 Deruxtecan molecules per BSA for immunization or immunoassay development. The final conjugate is lyophilized from PBS containing sugar-based stabilizer for easy shipment and storage.
The product is sold as either 1 vial of 1 mg (Cat# CM52140-1MG) or 5 vials of 1 mg (Cat# CM52140-5MG). For bulk orders, please contact us for a quote.
Application
- Assay development for the quantitation and detection of Deruxtecan or Deruxtecan metabolites in vitro or in vivo.
- Antibody discovery via immunization and hapten recognition
- Indirect and competitive ELISA assay
Key Features
- Lyophilized powder and ready for usage after reconstitution with water, no need for external buffer.
- Optimized loading with an average 3 to 5 Deruxtecan molecules per BSA
- Amount accurately determined by UV/HPLC analysis.
Selected References for Deruxtecan ADC
1) Takashi Nakada, et al. Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads. Bioconjugic & Medicinal Chem. Lett. 2016;26: 1542–45.
2) Yusuke Ogitani, et al. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016;107(7):1039−46.
3) Naoki Takegawa, et al. DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance. Int. J. Cancer. 2017;141:1682-89.
